In short
Emrusolmin, also known as TEV-56286, is currently being studied in clinical trials as a potential treatment for Multiple System Atrophy (MSA). This article provides an overview of the ongoing research, including the study design, objectives, and key information for patients considering participation in the trial.
At a glance
- Study Drug
- Emrusolmin (TEV-56286)
- Condition Studied
- Multiple System Atrophy (MSA)
- Study Phase
- Phase 2
- Study Design
- Multi-centered, Double-blind, Randomized, Placebo-controlled
- Primary Objective
- Evaluate efficacy of Emrusolmin in treating MSA
- Main Eligibility Criteria
- Adults ≥30 years, diagnosed with MSA, able to walk 10 meters
- Treatment Duration
- 48 weeks
- Primary Endpoint
- Change in modified UMSARS part I score from baseline to week 48
- Key Secondary Endpoints
- Total UMSARS score, CGI-S, MSA-QoL, Safety assessments
- Maximum Daily Dose
- 300 mg
- Administration Route
- Oral use
What is EMRUSOLMIN?
EMRUSOLMIN, also known as TEV-56286 or ANLE138b, is a new drug being developed to treat Multiple System Atrophy (MSA), a rare neurological disorder. It comes in the form of a capsule and is taken orally (by mouth). The chemical name for EMRUSOLMIN is 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole, which might sound complicated, but it's simply the scientific way of describing the drug's structure.
Multiple System Atrophy: The Target Condition
Multiple System Atrophy (MSA) is a rare, progressive neurological disorder that affects multiple systems in the body. It causes problems with movement, balance, and automatic body functions like blood pressure control. Currently, there is no cure for MSA, which is why the development of drugs like EMRUSOLMIN is so important for patients suffering from this condition.
Clinical Trial Details
EMRUSOLMIN is currently being studied in a Phase 2 clinical trial. This trial is designed to be:
- Multi-centered: The study is taking place at multiple hospitals or research centers.
- Double-blind: Neither the patients nor the doctors know who is receiving the real drug or a placebo.
- Randomized: Patients are randomly assigned to either receive EMRUSOLMIN or a placebo.
- Placebo-controlled: Some patients will receive a placebo (a pill with no active ingredient) to compare the effects with those who receive the real drug.
The study will last for 56 weeks (about 1 year and 1 month).
Eligibility Criteria
Not everyone with MSA can participate in this study. Here are some key eligibility criteria:
Inclusion Criteria:
- Patients must be 30 years or older.
- They must have "clinically possible" or "clinically probable" MSA, as determined by specific medical criteria (Gilman criteria).
- Patients must be able to walk at least 10 meters without another person's help, though they can use devices like a walker or cane.
Exclusion Criteria:
- Patients with any significant uncontrolled medical or psychiatric conditions that could interfere with the study.
- Those who are severely affected by MSA (with a specific score on a medical scale).
- Patients suspected of having a neurodegenerative disease other than MSA.
Study Objectives
The main goal of this study is to evaluate how well EMRUSOLMIN works in treating adults with MSA. Researchers also want to:
- Look at specific ways the drug might be effective beyond the main measure.
- Assess how safe EMRUSOLMIN is and how well patients tolerate it.
Endpoints: Measuring the Drug's Effectiveness
To determine if EMRUSOLMIN is working, researchers will look at several factors:
Primary Endpoint:
The main measure is the change in a modified version of a scale called UMSARS part I. This scale helps assess the severity of MSA symptoms.
Secondary Endpoints:
- Total UMSARS score (combining parts I and II of the scale).
- CGI-S: A scale that measures the overall severity of the illness.
- MSA-QoL: A measure of the quality of life for MSA patients.
Safety Considerations
The researchers will closely monitor the safety of EMRUSOLMIN by looking at:
- The number and percentage of participants experiencing side effects.
- How many patients leave the study due to side effects.
- Changes in vital signs (like blood pressure or heart rate).
- Changes in laboratory test results (blood tests).
- Changes in ECG measurements (heart rhythm tests).
It's important to note that EMRUSOLMIN has been designated as an orphan drug (EU/3/22/2652), which means it's being developed specifically for a rare disease. This designation can help speed up the development and approval process for drugs that treat rare conditions.